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Gene expression profiling of diffuse large B-cell lymphoma (DLBCL) has revealed prognostically 
important subgroups: germinal center B-cell-like (GCB) DLBCL, activated B cell-like (ABC) DLBCL, and 
primary mediastinal large B-cell lymphoma. The t(14;18)(q32;q21) has been reported previously to 
define a unique subset within the GCB-DLBCL. We evaluated for the translocation in 141 cases of DLBCL 
that were successfully gene expression profiled. Using a dual-probe fluorescence in situ hybridization 
assay, we detected the t(14;18) in 17% of DLBCLs and in 34% of the GCB subgroup which contained the 
vast majority of positive cases. In addition, 12 t(14;18)-positive cases detected by polymerase chain 
reaction assays on additional samples were added to the fluorescence in situ hybridization-positive 
cases for subsequent analysis. Immunohistochemical data indicated that BCL2, BCL6, and CD10 protein 
were preferentially expressed in the t(14;18)-positive cases as compared to t(14;18)-negative cases. 
Within the GCB subgroup, the expression of BCL2 and CD10, but not BCL6, differed significantly between 
cases with or without the t(14;18): 88% versus 24% for BCL2 and 72% versus 32% for CD10, respectively. 
In the GCB-DLBCL subgroup, a heterogeneous group of genes is overexpressed in the t(14;18)-positive 
subset, among which BCL2 is a significant discriminator. Interestingly, the t(14;18)-negative subset is 
dominated by overexpression of cell cycle-associated genes, indicating that these tumors are 
significantly more proliferative, suggesting distinctive pathogenetic mechanisms. However, despite this 
higher proliferative activity, there was no significant difference in overall or failure-free survival between 
the t(14;18)-positive and -negative subsets within the GCB subgroup. 
 
Diffuse large B-cell lymphoma (DLBCL) is an aggressive malignancy of mature B cells with an annual 
incidence of ∼25,000 cases in the United States. DLBCL is a heterogeneous entity both clinically and 
morphologically. We have recently shown by gene expression profiling that DLBCL can be classified into 
two major subgroups.1 The germinal center B-cell-like (GCB) subgroup expresses genes characteristic of 
normal GC B cells and is associated with a good outcome after multiagent chemotherapy, whereas the 
activated B-cell-like (ABC) subgroup expresses genes characteristic of activated blood B cells and is 
associated with a poor clinical outcome. Nonetheless, considerable molecular heterogeneity exists 
within each subgroup. A small number of DLBCL cases are unclassifiable and do not express the GCB or 
ABC signature genes at a high level.2 More recently, primary mediastinal large B-cell lymphoma (PMBL) 
has been identified as a distinct subgroup of DLBCL that can be distinguished by gene expression 
profiling from GCB- and ABC-DLBCL.3 and 4 
The t(14;18)(q32;q21) is a characteristic feature of follicular lymphoma and is considered to be the 
initiating event in lymphomagenesis. The t(14;18) is the result of an error during the process of VDJ 
recombination, leading to deregulation of the expression of the anti-apoptotic gene BCL2 by bringing it 
into proximity of the immunoglobulin heavy chain (IgH) gene enhancer. 5, 6, 7 and 8 In our initial study of 
35 cases of DLBCL, we correlatedBCL2 translocation data with gene expression profiles and showed that 
the t(14;18) defines a unique subset of DLBCL within the GCB subgroup. 9 This observation suggested 
that important genetic lesions are associated with a unique, identifiable gene expression profile. To 
substantiate and further extend this finding, we have examined 141 new cases that were part of 240 
cases of DLBCL studied by cDNA microarray for molecular predictors of survival after 
chemotherapy.2 These 141 cases of DLBCL with gene expression profiles, clinical data, and genetic data 
for BCL2 translocation were studied to determine: 1) the distribution of the t(14;18) among the 
subgroups of DLBCL identified by gene expression profiling; 2) whether t(14;18)-positive cases have a 
unique gene expression profile; and 3) whether there are differences in the tumor characteristics and 
clinical behavior between cases with and without the t(14;18). 
 
Materials and Methods 
Patient Information 
We studied 240 previously analyzed cases of DLBCL with clinical data and gene expression profiles 
determined by complementary DNA (cDNA) microarray technology.2A panel of hemopathologists 
including E Campo, ES Jaffe, G Ott, HK Müller-Hermelink, J Delabie, R Gascoyne, T Grogan, DD 
Weisenburger, and WC Chan confirmed the diagnosis of DLBCL and excluded the presence of follicular 
lymphoma in all patients. Informed consent was obtained and the Institutional Review Board of the 
University of Nebraska approved this study. 
Preparation of Tissue Microarrays (TMAs) and Immunohistochemical Studies 
TMAs were prepared from cases with adequate archival paraffin-embedded tissue. Hematoxylin and 
eosin-stained sections from each paraffin-embedded, formalin-fixed block were examined to define 
diagnostic areas and two to five (average, four) representative 0.6-mm cores were obtained from each 
case and inserted in a grid pattern into a recipient paraffin block using a tissue arrayer (Beecher 
Instruments, Silver Spring, MD). Five μm sections were then cut from each TMA and stained with 
antibodies to BCL2, BCL6, and CD10 as described.10 CD20 stains were performed to evaluate each core 
for involvement by tumor, and each case was evaluated independently by two pathologists (CPH, DDW) 
for the percentage of tumor cells stained and recorded in 10% increments. Disagreements were 
resolved by joint review on a multihead microscope. For each case, the core with the highest percentage 
of tumor cells stained was used for analysis. Cases were considered positive if 30% or more of the tumor 
cells were stained with an antibody.10 
Detection of the t(14;18)(q32;q21) by Fluorescence in Situ Hybridization (FISH) 
Among the 240 cases studied by gene expression profiling, 129 cases were studied by interphase FISH 
for the presence of the t(14;18)(q32;q21). To perform FISH studies, 4-μm sections were cut from the 
TMA paraffin blocks and mounted on positively charged slides. The sections were dewaxed in three 
changes of HEM-D (Scientific Safety Solvents, Keller, TX) followed by dehydration in 95% ethanol. They 
were then treated with 0.2 N HCl for 15 minutes, rinsed in distilled-deionized water, and incubated in a 
sodium thiocyanate solution at 80°C for 15 minutes. After rinsing in phosphate-buffered saline (PBS), the 
sections were digested with a protease solution at 37°C for 10 minutes; postfixed in 0.95% 
formaldehyde solution/PBS with 0.45% MgCl2 for 5 minutes at room temperature; rinsed in PBS; and 
sequentially dehydrated in 70%, 80%, and 95% ethanol. 
For FISH, the dual-color LSI IgH Spectrum Green/LSI BCL2 Spectrum Orange Dual-Fusion Translocation 
Probe (Vysis, Downers Grove, IL) was used to detect the t(14;18), and the CEP 18 Spectrum Aqua probe 
(Vysis) was used simultaneously to evaluate the chromosome 18 copy number. The probe mixture (10 
μl) was placed on the tissue sections, coverslipped, and sealed. Hybridization was performed overnight 
at 37°C using an automated hybridization chamber (HYBrite, Vysis) after denaturation at 75°C for 5 
minutes. The slides were washed in 2× standard saline citrate/0.1% Nonidet P-40 for 2 minutes at 72°C 
and then at room temperature for 2 minutes. Nuclei were counterstained with 4,6-diamidino-2-
phenylindole at a concentration of 125 ng/ml in anti-fade solution and the slides were visualized using 
an Olympus BX52 fluorescence microscope. Images were captured and archived using Cytovision 
software (Applied Imaging, Santa Clara, CA). To analyze the hybridization, a total of 50 to 100 nuclei 
were scored per case for the presence of the t(14;18). In normal cells, an interphase nucleus will exhibit 
individual red (BCL2) and green (IgH) signals. When the t(14;18) occurs, the red and green signals form 
two yellow fusion signals in the interphase cell. It has been established by the University of Nebraska 
Medical Center Human Genetics Laboratories that reactive lymphoid tissues show <2% positive cells at 
2.5 SD for this FISH assay. 
Detection of BCL2 Gene Rearrangement by Polymerase Chain Reaction 
Extracted DNA from all 240 cases was tested for the t(14;18) by the polymerase chain reaction (PCR). 
Amplification of the BCL2/JH translocation at the major breakpoint region (mbr) and minor cluster 
region (mcr) was performed as described previously. 11 Positive controls consisted of DNA extracted 
from the human B-cell lymphoma cell lines RL-7 for the mbr and DHL-16 for the mcr. Negative controls 
consisted of sterile water instead of DNA, and DNA from normal peripheral blood mononuclear cells 
obtained from healthy donors. Standard precautions were taken to guard against PCR contamination. 
The PCR-positive cases were added to the FISH-positive cases to form a final set of 34 cases with the 
t(14;18). The FISH-negative cases comprised the t(14;18)-negative group. 
Analysis of Differential Gene Expression 
We used the recently published Bayesian classification system to define the GCB, ABC, and unclassifiable 
subgroups of DLBCL.12 We also separated cases with the PMBL gene expression profile3 into a new 
subgroup, and examined the t(14;18) within each of these subgroups. The presence or absence of 
the BCL2 translocation was used to supervise the discovery of differentially expressed genes between 
the t(14;18)-positive and -negative cases in the GCB subgroup. The two-tailed Student's t-test was used 
to compare the differences in gene expression levels. Genes differentially expressed between the two 
subsets with a P value of <0.01 were selected for further analysis using the Significance Analysis of 
Microarrays (SAM) approach, as described previously. 13 In addition to the P value, we also calculated 
the t-statistics between the two groups and only genes that differed by a magnitude of >2.6 were 
selected for further analysis. 
As previously described, of the three different BCL2 clones (232714, 342181, 1336385) on the 
Lymphochip microarray, only clone 232714 with a more 5′ sequence could detect message with a 
truncated 3′ end because of translocation at the mbr. Overexpression ofBCL2 as measured by clone 
232714 was highly correlated with the BCL2 translocation. However, clone 232714 is located far from 
the 3′ end of the transcript and, therefore, may fail to measure much of the cDNA transcribed by reverse 
transcription reactions starting from the poly-A tail of the normal BCL2 transcript. We used the mean 
values measured by the BCL2 clones that are located close to the 3′ end (342181, 1336385) of the 
transcript to represent the gene expression level in cases in which this mean value was greater than the 
measurement by clone 232714. 
Survival Analysis 
The Kaplan-Meier method was used to estimate the overall and event-free survival of the patients, and 
the log-rank test was used to compare the survival experiences between the t(14;18)-positive and -
negative cases. Overall survival was defined as the time from diagnosis to death from any cause or, for 
patients remaining alive, the time from diagnosis to last contact. Event-free survival was defined as the 
time from diagnosis to the first occurrence of relapse or death from any cause or, for patients remaining 
alive and relapse-free, the time from diagnosis to last contact. SAS software (SAS Institute Inc., Cary, NC) 
was used for the data analysis. 
 
Results 
Occurrence of the t(14;18) in DLBCL 
Based on the results of our recent study of PMBL,3 12 GCB cases were reclassified as PMBL. Therefore, 
we classified the DLBCL cases into GCB, ABC, PMBL, and unclassifiable subgroups and examined the 
distribution of the t(14;18). Interphase FISH was applied to the 129 TMA cases and detected 22 cases 
that were positive for the t(14;18). Based on FISH analysis, t(14;18) was detected in 17% (22 of 129) of 
the cases of DLBCL which represented 34% (19 of 55) of the cases in the GCB subgroup. We also 
performed PCR assays on 240 cases studied by cDNA microarray, 26 cases were found to be positive, 
including 14 of the cases previously found to be positive by FISH (Figure 1). The PCR-negative cases that 
were not tested by FISH were excluded from further analysis because of the recognized high false-
negative rate of the PCR assay. Thus, PCR analysis revealed an additional 12 positive cases and in this 
cohort of 141 cases, 34 DLBCL cases carried the t(14;18) translocation, and 107 lacked this abnormality 
(Figure 1). 
 
 
Figure 1.  Frequency of the t(14;18) in DLBCL. A: Among the 129 cases studied by interphase FISH for the presence of t(14;18), 
22 cases were positive whereas 107 cases were negative. B: PCR analysis detected 26 positive cases, of which 14 were also 
shown to be positive by FISH. Therefore, an additional 12 positive cases detected by PCR were included in this study. Thus, of 
the 141 cases, 34 cases were BCL2 translocation-positive and 107 were negative. 
 
Review of the frequency of this anomaly in relation to the DLBCL subgroups (ie, GCB, ABC, PMBL, and 
unclassifiable) showed that the great majority (29 of 34) of the t(14;18)-positive cases occurred in the 
GCB subgroup. In contrast, only 3 cases occurred among the 23 cases in the unclassifiable subgroup, and 
none among the 41 ABC cases. Interestingly the t(14;18) translocation was found in 2 of the12 cases 
categorized by gene expression profiling as PMBL3 (Figure 2). 
 
 
 
Figure 2.  Distribution of the t(14;18) among the DLBCL subgroups. Twenty-nine of 34 positive cases occurred in the GCB 
subgroup, whereas three cases occurred in the unclassifiable subgroup and none in the ABC subgroup. Among 12 PMBL cases 
identified using the PMBL predictor, 2 cases had the t(14;18). 
Comparison with Immunohistochemical Data from the TMA 
We reviewed the immunohistochemical reactions of 109 TMA samples to correlate the presence and 
absence of the t(14;18) translocation with the expression of three relevant proteins, namely BCL-2 
(encoded by the gene deregulated by the translocation) and two markers of normal germinal center B 
cells (BCL6 and CD10). 
The protein expression of BCL2 was similar in the GCB (28 of 50, 56%) and ABC (19 of 31, 61%) 
subgroups, but was less frequent in the unclassifiable (6 of 19, 31%) or the PMBL subgroups (2 of 9, 
22%). The difference did not reach statistical significance (P = 0.054) ( Table 1). Within the GCB subgroup 
there was a significant difference (P < 0.0001) in BCL2 protein expression between thet(14;18)-positive 
cases (88%) and t(14;18)-negative cases (24%) ( Table 2) indicating that the t(14;18) is highly associated 
with BCL2 protein expression in this subgroup. In other subgroups BCL2 was generally up-regulated by 
mechanisms other than the t(14;18), as frequently seen in the ABC cases. 
 
Table 1. Expression of BCL2, BCL6, and CD10 in DLBCL Subgroups 
 
 
 
 
 
Table 2.  Expression of BCL2, BCL6, and CD10 with Regard to BCL2 Translocation 
 
 
BCL6 protein was detected in 58% (63 of 109) of the cases of DLBCL and it was very frequently expressed 
in the GCB subgroup (42 of 50, 84%; P < 0.0001), but within this category there was no correlation with 
the t(14;18) translocation ( Table 3). CD10 protein expression was detected overall less commonly than 
BCL6 (28%, 31 of 109), and the great majority of these cases (26 of 31) were in the GCB subgroup (Table 
1). This accounted for the fact that CD10 expression was much commoner overall in t(14;18)-positive 
cases than in t(14;18)-negative cases (67% versus 15%; P < 0.0001) ( Table 2). 
 
Table 3.  Expression of BCL2, BCL6, and CD10 in GCB DLBCL Cases According to BCL2 Translocation Status 
 
 
Differential Gene Expression between t(14;18)-Positive and t(14;18)-Negative Cases in GCB-DLBCL 
To search for genes that are differentially expressed between the t(14;18)-positive and t(14;18)-negative 
cases in the GCB subgroup, we examined all informative genes among 7399 known or uncharacterized 
genes on the Lymphochip.2 Clones with a P value of <0.01 were selected for SAM analysis. 13 Among the 
146 clones selected, 53 clones were overexpressed in the t(14;18)-positive group and 93 clones were 
overexpressed in the t(14;18)-negative group. The genes that were overexpressed in the t(14;18)-
positive group represented a heterogeneous set including genes involved in apoptosis 
(BCL2,BAD, DRAK1, and TXBP151), a number of transcription factors (FLI1, HOX11, andBAP135) and 
genes associated with cell adhesion/migration (CD62L, cytohesin-1,profilin 2, SDF1, and CD31). 
Interestingly, a large number of genes overexpressed in the t(14;18)-negative group are associated with 
cell cycle progression and regulation (Figure 3A). These include genes that control several events in 
mitosis (PLK, KNSL5,TTK, P55CDC, ARK2, CENE, and CENF), genes involved in cell cycle progression 
(CYCLIN-A, CDC2, CDC25C, and SAK) and DNA replication (HMG-I/Y, DNA helicase, and DHFR). 
  
Figure 3.  Differential gene expression in the two cytogenetic subsets of GCB-DLBCL. A: Differential expression of genes in cases 
with or without t(14;18) in the GCB subgroup. Differentially expressed genes are illustrated with red indicating increased 
expression and green decreased expression. Each column represents a single GCB DLBCL case and each row represents a single 
gene. Among the 146 clones selected, 53 clones were overexpressed in the t(14;18)-positive group and 93 clones were 
overexpressed in the t(14;18)-negative group. Genes discussed in the text are listed on the right with the number of clones 
selected (when >1) indicated in the bracket. The full gene list is available in the supplemental table 
at http://ajp.amjpathol.org. B: BCL2 gene expression in cases with and without the t(14;18) in the GCB subgroup. BCL2 gene 
expression was calculated as detailed in the text to more accurately reflect the true expression levels. These new values 
avoided the false-negative measurements because of 3′ truncation of the transcript resulting from BCL2 translocation at the 
mbr and the falsely low values on many normal transcripts, when measured by the clone (232714). Using these values, BCL2 is 
significantly overexpressed in the t(14;18)-positive subset (P = 0.0015 and t-statistic value = 3.35). 
 
Some of the cDNAs were represented by multiple clones on the array and these clones were selected 
independently by the computer algorithm, providing confidence in the reproducibility of the 
experimental data and the analytical approach. BCL2 gene expression by the different cDNA clones had 
been adjusted to obtain a more accurate measurement as described in the Materials and Methods 
section. It was found to be a highly significant discriminator between the two cytogenetic groups (Figure 
3B). 
Correlation between the t(14;18) and Survival in the GCB Subgroup 
The GCB subgroup (excluding PBML) consisted of 39 men and 26 women with a median age of 61 years 
(range, 24 to 88 years). The median follow-up of the surviving patients was 7.3 years (range, 0.8 to 21.8 
years) in this group. Figure 4, A and B, shows Kaplan-Meier estimates of overall and event-free survival 
experiences, respectively, of the t(14;18)-positive and negative subsets of the patients in the GCB 
subgroup as defined by the Bayesian classifier. P values are based on a log-rank comparison of the 
outcome of the two subsets. There is no significant difference between the two cytogenetic subsets. 
 
 
 
 
 
Figure 4.  Survival of t(14;18)-positive versus t(14;18)-negative patients in the GCB DLBCL 
subgroup. A: Overall survival; B: event-free survival. There is no significant difference 0in survival 
between the two subsets of patients. 
 
Discussion 
DLBCL is the most common type of lymphoma, comprising 30 to 40% of all non-Hodgkin's 
lymphoma.14 The recent development of DNA microarray technology provides an opportunity to take a 
genome-wide approach to the study of DLBCL. We have previously identified two molecularly distinct 
subtypes of DLBCL indicative of different functional stages of B-cell differentiation.1 and 2 One type 
expressed genes characteristic of GC B cells (GCB-DLBCL), whereas the other type expressed genes 
normally seen during in vitro activation of peripheral blood B cells (ABC-DLBCL). In a previous study, 9we 
found that the t(14;18)-positive cases of DLBCL were all in the GCB group but, because of the limited 
number of cases, a number of interesting questions could not be addressed. In this study, we have 
examined the presence of the t(14;18) in a much larger series of DLBCL and have correlated this genetic 
abnormality with the gene expression profiles, tumor characteristics, and survival of the patients. The 
FISH assay detected the t(14;18) in 17% (22 of 129) of the cases and in 34% (19 of 55) of the GCB cases, 
similar to our previous findings.9 By PCR analysis, we detected the translocation in an additional 12 cases 
outside of the cohort studied by FISH. We observed that the vast majority (29 of 34) of the t(14;18)-
positive cases occurred in the GCB subgroup. These cases had a gene expression profile resembling 
normal GCB cells, suggesting that this translocation plays an important role in the pathogenesis of this 
subset of DLBCL, just as it does in follicular lymphoma. The complete absence of t(14;18) in the ABC-
DLBCL confirmed our previous observation and supported the conclusion that GCB and ABC DLBCL are 
distinct pathogenetic and biological entities. Three t(14;18)-positive cases were found in the 
unclassifiable subgroup. However the unclassifiable cases are not well characterized and are 
heterogeneous, likely including some GCB cases with atypical profiles. Recently, Rosenwald and 
colleagues3 and Savage and colleagues4 have defined a unique gene expression profile for PMBL and this 
subgroup can now be distinguished from the GCB-DLBCL. It is interesting to note that a low percentage 
(22%) of PMBL cases had the t(14;18), suggesting that there may be further heterogeneity within this 
subgroup. 
We also analyzed the immunohistochemical findings available in the cases with t(14;18) data. The vast 
majority of patients with this translocation had increased BCL2 protein expression. However, BCL2 
protein was also frequently present in cases without the translocation, especially in the ABC subgroup, 
which characteristically had high BCL2 mRNA levels. This indicates that up-regulation of BCL2 expression 
may occur by other mechanisms such as activation of the nuclear factor-kB pathway or an increased 
copy number of the BCL2 gene. It is interesting to note that, in the GCB subgroup, BCL2 protein 
expression was markedly different in cases with and without the t(14;18) (89%versus 37%, respectively). 
BCL6 protein was more frequently expressed in the GCBversus the ABC and other subgroups, but was 
not specifically correlated with the t(14;18) within the GCB subgroup. On the other hand, CD10 
expression was highly specific for the GCB subgroup and was most frequently expressed in cases with 
the t(14;18). In the PMBL subgroup, the majority have the immunohistochemical profile of the t(14;18)-
negative cases, as expected. 
We also attempted to correlate the t(14;18) status with gene expression profiles within the GCB 
subgroup to discover genes that characterize the two cytogenetic subsets and might provide insight into 
their pathobiology. SAM analysis was used to find genes that were differentially expressed between the 
two subsets after an initial data reduction based on the Student's t-test (P < 0.01). SAM analysis 
identified 53 up-regulated genes in the t(14;18)-positive cases and 93 up-regulated genes for t(14;18)-
negative cases.BCL2 gene expression is an important discriminator between the two cytogenetic 
subsets. BCL2 was overexpressed in most cases of GCB-DLBCL with the t(14;18). However, there were a 
few cases in which BCL2 expression was low, indicating that overexpression of this gene may no longer 
be necessary in some cases of established DLBCL. The microarray analysis was further substantiated by 
BCL2 immunohistochemistry, which revealed that a high percentage (88%) of t(14;18)-positive GCB-
DLBCL cases had BCL2 protein expression, whereas BCL2 was expressed in only 24% of the t(14;18)-
negative cases. In addition to BCL2, several genes that may be involved in apoptosis were also 
overexpressed in t(14;18)-positive cases including BAD, a proapoptotic gene in the BCL2 family. DRAK1, 
a positive mediator of apoptosis, is related to Death-associated Protein Kinase 1 (DAP1). 15 TXBP151 is a 
novel anti-apoptotic gene that has been shown to mediate the activity of A20, which is induced by 
CD40/CD40L interaction, 16 and 17 and its proteolysis is associated with FAS-mediated apoptosis. IL15 was 
also overexpressed in the BCL2 translocated cases and it has been implicated in protecting B cells from 
apoptosis. 18 The precise functional alterations in the apoptotic pathway are difficult to predict from the 
gene expression data and it is possible that the apoptotic pathway is dominated by BCL2 overexpression 
in the vast majority of t(14;18)-positive cases. In addition to these genes, there is also overexpression of 
a heterogeneous group of transcription factors including FLI1 that regulates expression of the TGF-β 
type II receptor, 19HOX11 that belongs to a family of DNA-binding transactivators, 20 and BAP135. 
BAP135 exists as a complex with Bruton Tyrosine Kinase (BTK) before B-cell antigen receptor 
engagement and is transiently tyrosine-phosphorylated in response to B-cell receptor cross-
linking. 21BAP135 is identical to the putative transcription factor TFII-I and there is evidence that tyrosine 
phosphorylation may enhance its activity, thereby linking receptor activation with changes in gene 
expression. A group of genes that have diverse functions were also overexpressed including a number of 
genes that are involved in cell adhesion, migration, and cytoskeletal function: CD62L, cytohesin-
1, profilin 2, SDF1, and CD31. CD62L is involved in cell adhesion and migration. 22 Cytohesin-1 is a 
guanine nucleotide exchange factor for ARF GTPases and is a regulator of integrin-mediated cell 
adhesion.23 The function of integrins is regulated through cytoplasmic signaling, and profilin 224 may 
form an important link between integrin cell adhesion signals and F-actin polymerization, as has been 
postulated in T lymphocytes.25 SDF1 is a highly potent lymphocyte chemoattractant and is also involved 
in intracellular actin polymerization in lymphocytes, a prerequisite for cell motility.26 CD31 has 
widespread distribution and in addition to cell adhesion, may have a role in regulating cell signaling and 
angiogenesis. 27 and 28 
The gene expression profile associated with t(14;18)-negative cases was dominated by genes involved in 
cell cycle progression and regulation. These included genes involved in regulating mitotic spindle 
functions, activation of anaphase promoting complex (APC) and events essential for cytokinesis 
(eg, PLK, mitotic kinesin-like protein-1, or KNSL5,P55CDC, and CKS1). 29, 30, 31 and 32 In addition to these 
genes, many important regulators of cell cycle-related events including centrosome 
separation/segregation (eg,ARK2), 33 kinetochore association (eg, CENF), 34 functional components of 
mitotic check points (eg, CENPE and TTK orMps1), 35 and 36 chromatin association and DNA replication 
(eg, HMG-I/Y, chromatin assembly factor-I (p150), DNA helicase and DHFR).37, 38 and 39 A group of genes 
that promotes G2/M transit or are expressed in the M phase of the cell cycle, including CYCLIN-
A, CDC2, CDC25C, and SAK, 40, 41 and 42 were also up-regulated. These results suggest that t(14;18)-negative 
GCB-DLBCL is significantly more mitotically active than the t(14;18)-positive cases, and indicates that the 
two cytogenetic subsets have distinctive biological characteristics. In normal cells, BCL2 has been 
reported to retard G1/S phase progression43 and the higher expression of BCL2 in the translocated cases 
may have the same effects on cell cycle progression as has been observed in developing B 
lymphocytes.44 However, further studies are needed to determine whether other mechanisms are 
involved in the higher expression of genes associated with cell cycle regulation and progression in the 
nontranslocated subset. 
Overall and failure-free survival analysis did not show any significant differences between t(14;18)-
positive and -negative cases within the GCB subgroup. However, there seems to be a continued 
occurrence of late deaths in the t(14;18)-positive subset but this finding needs to be confirmed in a 
larger series of patients. 
In conclusion, we found that t(14;18) was present in a large subset of cases in the GCB-DLBCL subgroup. 
This specific translocation was primarily confined to GCB-DLBCL, without any cases seen in ABC-DLBCL, 
thus supporting the view that DLBCL can be divided into pathogenetically distinct subgroups with unique 
gene expression profiles. Cases in the ABC subgroups also frequently overexpressed BCL2, but through 
mechanisms other than t(14;18). The t(14;18)-positive subset within the GCB subgroup showed a clear 
decreased expression of proliferation signature genes when compared with the t(14;18)-negative 
subset. This could be partly explained by the anti-proliferation effect of BCL2, but there may be other 
underlying biological mechanisms. These two subsets did not show any significant differences on 
survival under conventional therapy. However, the increase in BCL2 expression in one subset and the 
higher proliferative activity in the other suggest biological differences that could be exploited in future 
clinical trials. 
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